微生态制剂预防和治疗婴幼儿湿疹临床观察.docVIP

微生态制剂预防和治疗婴幼儿湿疹临床观察 　　摘要：目的 观察微生态制剂预防和治疗婴幼儿湿疹的临床价值。对确诊湿疹的患儿进行治疗，7 d后观察疗效是否改善，1个月后观察复发率是否降低。方法 将2013年1月～8月我院门诊确诊的湿疹患儿73例随机分为治疗组（n=37）；对照组（n=36）。对照组采用丁酸氢化可的松乳膏外用联合氯雷他定糖浆口服综合治疗。治疗组则再给予培菲康口服治疗。7 d后观察两组的临床疗效和特应性皮炎评分标准（ SCORAD 评分），1个月后统计湿疹复发率。结果 治疗组的临床疗效明显优于对照组（P0.01）；治疗组的 SCORAD 评分明显优于对照组（P0.01）；治疗组1个月内的复发率明显低于对照组（P0.01）。同时，治疗组的消化不良症状改善情况明显优于对照组。结论 微生态制剂预防和治疗婴幼儿湿疹的临床效果显著，值得临床推广。 　　关键词：微生态制剂；湿疹；过敏性疾病 　　Clinical Analysis on the Prevention and Treatment of Microecologics to Infantile Eczema 　　FENG Yi， CHANG Qing， CAI Yan 　　（Wuxi City No.8 Peoples Hospital， Wuxi， Jiangsu 214016， China） 　　Abstract：Objective： To evaluate the prevention and treatment effects of microecologics to infantile eczema. Methods： 73 children diagnosed as eczema during January to August 2013 were randomly divided into two groups. The control group were treated by Butyrate hydrocortisone cream and Loratadine syrup， while the observation group were given bifid triple viable on the basis of control group. The clinical effects and the severity scoring of atopic dermatitis（SCORAD index） of two groups were compared in 7-days treatment. One-month eczema recurrence rate of two groups were compared. Results： The curative effect of the treatment group was better than that of the control group（P0.01）. The SCORAD index of the treatment group decreased significantly（P0.01）. The control group tended to have higher recurrence rate（P0.01）. The improvement of indigestive symptom of the treatment group were better than control group（P0.01）. Conclusion： Microecologics has a significant effect on the prevention and treatment on infantile eczema. Thus， it is worth to clinical application. 　　Key words：Microecologics， Eczema， Allergic disease 　　过敏性疾病是婴幼儿常见的疾病之一，其患病率呈全球上升趋势。“卫生学假说”提出儿童早期对微生物接触减少，Th1/Th2免疫失衡是导致过敏性疾病发生的主要因素。早期患有过敏性疾病的儿童，长大后其过敏性皮炎、过敏性哮喘等过敏性疾病的发生率显著增高[1]。对过敏性疾病的研究，主要集中在环境因素和过敏耐受方面，目前流行病学调查资料和实验室研究认为，早期接触微生物可以促进机体对过敏原的耐受，而口服有益菌在此方面发挥了重要的作用[2]。为此，我院对2013年1月～8月的门诊湿疹患儿进行了口服益生菌的对照试验，取得了良好的疗效。 　　1资料与方法 　　1.1一